EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma

Michielsen, 2005, Viral hepatitis and hepatocellular carcinoma, World J Surg Oncol, 3, 27, 10.1186/1477-7819-3-27 McGlynn, 2006, A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States, Cancer Epidemiol Biomarkers Prev, 15, 1198, 10.1158/1055-9965.EPI-05-0811 Sangro, 2010, Gene therapy for liver cancer: clinical experience and future prospects, Curr Opin Mol Ther, 12, 561 Shi, 2009, An update on gene therapy in China, Curr Opin Mol Ther, 11, 547 Morille, 2008, Progress in developing cationic vectors for non-viral systemic gene therapy against cancer, Biomaterials, 29, 3477, 10.1016/j.biomaterials.2008.04.036 Xu, 2001, Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver, Proc Natl Acad Sci USA, 98, 15089, 10.1073/pnas.241522398 Sapra, 2005, Ligand-targeted liposomes for cancer treatment, Curr Drug Deliv, 2, 369, 10.2174/156720105774370159 Moreira, 2008, Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing, J Nanosci Nanotechnol, 8, 2184, 10.1166/jnn.2008.18270 de Fougerolles, 2007, Interfering with disease: a progress report on siRNA-based therapeutics, Nat Rev Drug Discov, 6, 443, 10.1038/nrd2310 Baker, 2010, RNA interference: homing in on delivery, Nature, 464, 1225, 10.1038/4641225a Tseng, 2009, Lipid-based systemic delivery of siRNA, Adv Drug Deliv Rev, 61, 721, 10.1016/j.addr.2009.03.003 Zimmermann, 2006, RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 10.1038/nature04688 Li, 2008, Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles, J Control Release, 126, 77, 10.1016/j.jconrel.2007.11.002 Li, 2008, Tumor-targeted delivery of siRNA by self-assembled nanoparticles, Mol Ther, 16, 163, 10.1038/sj.mt.6300323 Gao, 2011, The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes, Biomaterials, 32, 3459, 10.1016/j.biomaterials.2011.01.034 Giannelli, 2008, EGFR and VEGFR as potential target for biological therapies in HCC cells, Cancer Lett, 262, 257, 10.1016/j.canlet.2007.12.001 Dominska, 2010, Breaking down the barriers: siRNA delivery and endosome escape, J Cell Sci, 123, 1183, 10.1242/jcs.066399 Gao, 2010, Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing, Biomaterials, 31, 2655, 10.1016/j.biomaterials.2009.11.112 Liu, 2010, A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery, Biomaterials, 31, 9145, 10.1016/j.biomaterials.2010.08.053 Gao, 2009, PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity, Breast Cancer Res Treat, 115, 29, 10.1007/s10549-008-0043-0 Katas, 2006, Development and characterisation of chitosan nanoparticles for siRNA delivery, J Control Release, 115, 216, 10.1016/j.jconrel.2006.07.021 Chiu, 2002, RNAi in human cells: basic structural and functional features of small interfering RNA, Mol Cell, 10, 549, 10.1016/S1097-2765(02)00652-4 Li, 2004, Induction of RNA interference in dendritic cells, Immunol Res, 30, 215, 10.1385/IR:30:2:215 Chang, 2009, Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression, Recent Pat Anticancer Drug Discov, 4, 110, 10.2174/157489209788452830 Yin, 2008, Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene, Hepatology, 48, 1528, 10.1002/hep.22510 Kirpotin, 1997, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro, Biochemistry, 36, 66, 10.1021/bi962148u Zhang, 2010, DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery, Int J Pharm, 390, 198, 10.1016/j.ijpharm.2010.01.035 Garbuzenko, 2005, Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer, Chem Phys Lipids, 135, 117, 10.1016/j.chemphyslip.2005.02.003 Li, 2009, Nanoparticles evading the reticuloendothelial system: role of the supported bilayer, Biochim Biophys Acta, 1788, 2259, 10.1016/j.bbamem.2009.06.022 Brigger, 2002, Nanoparticles in cancer therapy and diagnosis, Adv Drug Deliv Rev, 54, 631, 10.1016/S0169-409X(02)00044-3 Gao, 2008, Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments, Mol Cancer Ther, 7, 3399, 10.1158/1535-7163.MCT-08-0514 Visaria, 2006, Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor alpha delivery, Mol Cancer Ther, 5, 1014, 10.1158/1535-7163.MCT-05-0381 Gao, 2010, Antibody engineering promotes nanomedicine for cancer treatment, Nanomedicine (Lond), 5, 1141, 10.2217/nnm.10.94